# (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 24 July 2008 (24.07.2008)

(51) International Patent Classification: GOIN 33/566 (2006.01) A61K 49/00 (2006.01) GOIN 33/574 (2006.01)

(21) International Application Number:

PCT/US2008/050994

(22) International Filing Date: 14 January 2008 (14.01.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

12 January 2007 (12.01.2007) 60/884,634 US

(71) **Applicant** (for all designated States except US): **UNIVER**¬ SITY OF SOUTH FLORIDA [US/US]; 3802 Spectrum Blvd., Suite 100, Tampa, FL 33612 (US).

- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HAURA, Eric, B. [US/US]; 2608 West Wyoming Avenue, Tampa, FL 3361 1 (US).
- (74) Agent: MCGAW, Michael, M.; 180 Pine Avenue North, Oldsmar, FL 34677 (US).

- (10) International Publication Number WO 2008/089135 A3
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### **Published:**

- with international search report
- (88) Date of publication of the international search report: 18 September 2008

(54) Title: IDENTIFICATION OF BIOMARKERS PREDICTIVE OF DASATINIB EFFECTS IN CANCER CELLS

(57) Abstract: A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected by dasatinib. Early phase trials of dasatinib are ongoing in cancer patients. It will be important to determine which patients receive a clinical benefit of dasatinib. Predetermination of treatment benefit can be performed by assessing biomarkers in patients tumors prior to treatment with dasatinib or other inhibitors of EGFR and SRC. Patients that have positive biomarkers for treatment could then be treated with higher confidence of benefit while those not possessing these predictive biomarkers would avoid ineffective and potentially toxic therapy. Additionally, treatment can be tailored according to predetermined sensitivity by evaluating indicated biomarkers correlating with sensitivity to one or more agents.

#### INTERNATIONAL SEARCH REPORT

International application No PCT/US 08/50994

### CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01 N 33/566, G01 N 33/574, A61 K 49/00 (2008.04)

USPC - 436/501, 435/7.23, 424/9.1

According to International Patent Classification (IPC) or to both national classification and IPC

#### B FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - G01N 33/566, G01N 33/574, A61K 49/00 (2008 04)

USPC - 436/501, 811, 64. 435/7 23, 424/9 1, 530/827

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched PUBWEST, GOOGLE SCHOLAR

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PUBWEST(PGPB  $_1$ USPT  $_1$ USOC ,EPAB  $_1$ JPAB), GOOGLE SCHOLAR gefitinib,  $\beta$ rlotinib, egfr, resistant, status, mutation, dasatinib, sprycel, bms-354825, inhibitor, antagonist, src, aal, cml, leukemia, bcr, abl

## C DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where approp $\pi$ ate, of the relevant passages	Relevant to claim No
X - Y	WO 2005/117888 A1 (Green et al.) 15 December 2005 (15 12 2005) pg 6, ln 3-19 and ln 26-32, pg 17, ln 13-16, pg 18, ln 3-8 and ln 29-30, pg 22, ln 17-21 and ln 25-28, and pg 27, ln 5-15 and ln 28-30	14, 15, 17, 24, and 25
<u>X</u> <u>Y</u>	SONG ET AL Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival Cancer Research June 2006, Vol 66 No 11 pages 5542-5548, especially pg 5542, col 1 and 2, pg 5543, col 2-pg5545, col 1, pg 5546, fig 3, pg 5548, col 1 and 2, and the abstract	1-10, 12-13, and 18-23
Y	US 2006/0235006 A1 (Lee et al.) 19 October 2006 (19 10 2006) para [0003]	11

## Further documents are listed in the continuation of Box C

D

- Special catego πes of cited documents
- 'A' document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on pno  $\pi$ ty claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- O" document referring to an oral disclosure, use, exhibition or other
- 'P'' document published  $p\pi or$  to the international filing date but later than
- "T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

18 Apr 2008 (18 04 2008)

Date of mailing of the international search report

2 7 JUN 200S

Name and mailing address of the ISA/US

the priority date claimed

| Mail Stop PCT, Attn ISA/US, Commissioner for Patents P O Box 1450, Alexand  $\pi a$ , Virginia 22313-1450

P O Box 1450, Alexandπa, Virginia 22313-1450 Facsimile No 571-273-3201 Authorized officer

Lθθ W Young

PCTH βlpdβsk 571-272-4300 PCT OSP 571-272 7774